Overview
Mercy Health is committed to fighting cancer in all its forms, and part of that fight is investing in medical research and clinical trials to find new ways to battle the disease.
Paducah, KY
updated 10/21/2025
Pharma-Studies open to recruiting
GS-US-595-6184 (ASCENT-05): NCT05633654
Randomized, open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After surgery and Neoadjuvant Therapy
Indication: Breast (Triple Neg)
CELC-G-302 (VIKTORIA-2) NCT06757634
A Randomized, Open-Label Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors with or without Gedatolisib as First-Line Treatment in Patients with HR-Positive and HER2-Negative Advanced Breast Cancer
Indication: Breast
MK-3475-587: NCT03486873
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
Indication: Any tumors
Registry trials - active and open for enrollment
TEMPUS TIME TRIAL (GEMINI TP-CA-002) NSCLC- NCT05236114:
A Longitudinal Multiomic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer
Indication: NSCLC
Studies to activate soon
TROPION- Lung 10: NCT06357533- Sponsor Trial through AstraZeneca
Phase 3, Randomized, Open-Label Global Study of Datopotamab Deruxtecan(Dato-DXd) in Combination with Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for First-Line Treatment of Patients with Locally-advanced or Metastatic Non-Squamous NSCLC with High PD-L1 Expression (TC >= 50%) and Without Actionable Genomic Alterations
Indication: NSCLC
Blood studies open to recruiting
MT1226: (BLOOD STUDY) The goal of this study is to collect whole blood from patients with Colorectal Cancer (CRC) with and without liver metastases. This is a prospective study requiring full patient consent for enrollment. Biologic material and clinical data must be provided and de-identified. Only the physician/CRC/pathology staff may have access to the confidential patient data.
Indication: Late-stage colorectal cancer
MT4901: This study is designed to evaluate biomarkers in biospecimens collected from patients with non-small cell lung cancer. This is a prospective study requiring full patient consent for enrollment. Biologic material and clinical data must be provided and de-identified. Only the physician/CRC/pathology staff may have access to the confidential patient data.
Indication: NSCLC
MT1819: Study of Whole Blood Samples from patients with cancer. The goal of this study is to evaluate biomarkers/molecular characteristics in blood from patients diagnosed with various cancers. This is a prospective study requiring full patient consent for enrollment. Biologic material and clinical data must be provided and de-identified. Only the physician/CRC/pathology staff may have access to the confidential patient data.
Indication: Cancer
MT2234: Fresh Blood Samples from Patients with Cancer and Benign Disease. This study is designed to evaluate biomarkers associated with cancer for diagnostic assay development. This is a prospective study requiring full patient consent for enrollment. Biologic material and clinical data must be provided and de-identified. Only the physician/CRC/pathology staff may have access to the confidential patient data.
Indication: CA & Benign Disease
MT2221: Study of Fresh Bone Marrow in patients with Multiple Myeloma Cancer with active disease >5% plasma cells
Indication: Multiple myeloma
MT1410-A: Evaluate Molecular Characteristics in the blood samples of patients with Ovarian or Pancreas-Any Stage Pre-TX/Surgery
Indication: Ovarian & Pancreatic
MT2875: Study of Fresh Blood & Urine from Patients with Pancreatic Cancer
Indication: Pancreatic
MT3060: Cohort P- ON HOLD
Study of Fresh Blood from Cancer patients scheduled to receive Keytruda(pembrolizumab)-NSCLC, HNSCC, TNBC, CRC
Indication: Solid Tumors
MT0332:
Study of Frozen Plasma and Buffy Coat from Patients with Stage IV NSCLC Receiving Immunotherapy
Indication: NSCLC
MT1118: ENTIRE STUDY ON HOLD
Study of Fresh Blood from Patients with Stage III-IV Breast Cancer, Colon Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, or Melanoma. These patients must be treatment naïve (preferred) or can be refractory to treatment at time of collection. If refractory, the patient MUST be enrolled after the cessation of therapy and BEFORE starting another line of therapy. If treatment Naïve, patient must be enrolled before the start of any treatment, or any surgery has been performed.
Indication: Specific tumors
Studies active, not recruiting
CELC-G-301 (VIKTORIA-1) NCT05501886- Closed for ENROLLMENT as of 09/16/2025
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
Indicator: Breast
LOXO-BTK-20019: NCT04662255
Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantel Cell lymphoma (BRUIN MCL-321)
Indicator: Mantle Cell Lymphoma
NCI Trial: COSMIC Trial (WF2304) NCT06418204
Registry Trial for Newly diagnosed with Breast, Colorectal, Melanoma, NHL, NSCLC looking to see how they manage cancer related symptoms
Indicator: Specific tumors